Mack Bio is a maverick in the biotechnology industry. We are a integral part of a fast growing and ever evolving industry - Nanomedicine. Nanomedicine is defined as a device or pharmaceutical on the scale of 1 nm to 300nm (nm - one billionth of a meter) in size. At this scale, we can interact one on one with bacteria, viruses, DNA, cells and tissues. Nano sized objects have always existed in nature but until recently, we as researchers, have learned to visualize and control these sizes of particles. From a financial standpoint, nanomedicine is currently a $212B market world-wide and is estimated to double in market growth and reach $ 528B by late 2019.
Some other companies involved directly in nanomdedicine today include: Ablynx NV, Celgene Corporation, Abraxis Bioscience Inc., Mallinckrodt PLC, GE Healthcare, Qiagen NV, Combimatrix Corp, Merck & Co. Inc., Pfizer Inc., Nanosphere, Inc., Arrowhead Research, and Teva Pharmaceutical Industries Ltd.
Mack Bio's mission is two fold. Our first goal is to provide a fast, efficient and safe pathway from concept to approval of new medical products. We are a new evolution of a focused and rapidly adapting developer of nanotechnology for medicine. We are driven to create design of medical technology based on nano and micron scale. Whether nanoparticles, micron printed systems or nano wave length light. We believe the solutions in medicine tomorrow will be based in this scale.
Our second focus is to partner with other biotech companies, designers and inventors in order to raise research funding and create synergy between these alliances. We offer a platform to fund new concepts as well as partner to fund clinical trials. Based on this synergy, we aspire to propel our strategic partners to the next level of development.
Our Six Biologically Based Corporate Attributes:
Mack Bio is a dynamic corporation offering the flexibility to react to the ever changing landscape of the medical field. What would normally take years to complete takes us months. We are already working on several novel projects with several partners to create real solutions for the both medical device and OTC pharmaceuticals markets.